



NEWS RELEASE

Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference

2016-05-26

WALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in the 13th Annual Craig-Hallum Institutional Investor Conference being held on June 1 in Minneapolis, MN. This conference provides institutional investors the opportunity to meet with Company management and does not include a formal presentation. Repligen's most recent investor presentation will be accessible through the **Investor Events** section of Company's website.

About Repligen Corporation

Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify monoclonal antibody therapeutics. Our ATF (Alternating Tangential Flow) systems and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we developed and market an innovative line of "ready-to-use" chromatography columns under our OPUS® and MediaScout® brands that we deliver pre-packed with our customers' choice of resin. Repligen's corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Lund, Sweden and Weingarten, Germany.

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could"

and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

Contact:
Sondra S. Newman
Senior Director Investor Relations
Repligen Corporation
(781) 419-1881
snewman@repligen.com

Source: Repligen Corporation